Clinical Trial Update: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of 3 Subcutaneous and 1 Intravenous Dose of E6011 in Subjects With Active Crohn's Disease [Phase 1]

View source ↗

Summary

A Phase 1 study evaluating E6011 in active Crohn's disease has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Crohn Disease

Drugs mentioned

• E6011

Snippet

Sponsor: Eisai Inc. | Conditions: Crohn's Disease | Phase 1 | Status: WITHDRAWN